Long Read Sequencing Market Identification and Fine Mapping of Structural Variation Segment to Contribute Largest Share

The long read sequencing is a DNA sequencing technique. It offers numerous distinct advantages than next-generation sequencing technologies such as more precisely sequence DNA containing the same sections of DNA repeated within the genome. Many adults aged 60 years and above suffer from two or more chronic illnesses. Genes play a role in chronic diseases such as cardiovascular disease, diabetes, obesity, RA, Alzheimer's disease (AD), and depression, according to twin research. According to the Centers for Disease Control and Prevention (CDC), about 6 out of 10 individuals in the US are affected by at least one chronic disease, as well as 4 out of 10 are suffering from two or more chronic diseases.

Download sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00006815/?utm_source=OpenPR&utm_medium=10144

The long read sequencing market was valued at US$ 1,101.15 million in 2020 and it is projected to reach US$ 5,334.68 million by 2028; it is expected to grow at a CAGR of 22.3% during 2021-2028.

Based on technology, the long read sequencing market is segmented into single-molecule real-time sequencing (SMRT), nanopore sequencing, and loop genomics long read sequencing. In 2020, the single-molecule real time sequencing (SMRT) segment accounted for the largest share of the market.

Oxford Nanopore Technologies; Tataa Biocenter; Illumina, Inc; Perkinelmer Inc.; F. Hoffmann-La Roche Ltd.; Baseclear B.V.; Bionano Genomics; Longas Technologies; Pacific Biosciences of California, Inc.; and Quantapore, Inc are among the key players operating in the long read sequencing market. These companies focus on partnerships, mergers, product launches, and collaborations to sustain their positions in the market.

For instance, in January 2021, Illumina Announced new sequencing system, collaboration with Roche, and software suite to accelerate genomics adoption. Furthermore, Roche will work with Illumina to add additional companion diagnostic (CDx) statements to Illumina's robust pan-cancer assay TruSight Oncology 500 (TSO 500). Moreover, in March 2021, The Oxford Nanopore Ultra-Long DNA Sequencing Kit, when used in conjunction with Circulomics Nanobind Kits, is designed to maximise the number of ultra-long reads and has allowed the continuous sequencing of single DNA fragments of up to 3+ Mb externally and 4+ Mb internally. Using this method, users can achieve more than 100 reads over 1 Mb per PromethION flow cell run.

The researchers were able to recognize and classify new forms of cancerous mutations using long-read technologies, including complex structural variants in haplotype resolution. In recent years, several long read sequencing technologies have been developed and used. For example, Pacific Biosciences developed SMRT sequencing, which is one of the long read methods (PacBio). Long read sequencing is becoming more common, and cancer studies based on long read data are growing and advancing in order to decode complex cancer genomes.

Place an order copy of this report @ https://www.theinsightpartners.com/buy/TIPRE00006815/?utm_source=OpenPR&utm_medium=10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

This release was published on openPR.